Mammalian spermatozoa are particularly susceptible to the deleterious effects of reactive oxygen species and lipid peroxidation, which ultimately lead to impaired fertility. A number of enzymes are present in the male reproductive tract which may play a role in preventing oxidative damage; in particular, the epididymis is the site of synthesis and secretion of large amounts of extracellular superoxide dismutase (eSOD). In order to study the distribution of eSOD in the male reproductive tract, and distinguish it from other related superoxide dismutase isoenzymes (e.g. cytosolic SOD), polyclonal antisera have been raised against a recombinant human eSOD fusion protein, expressed in bacterial cells. This protein was expressed from a synthetic gene fragment, using preferred Escherichia coli codons, designed to overcome the problems associated with the high guanineϩcytosine content of the natural human eSOD transcript. Using this antiserum, eSOD can be readily detected in a range of human reproductive tissues as well as in human seminal plasma. However, the presence of similar levels of eSOD in the seminal plasma of vasectomized men (probably of prostatic origin) precludes its use as a simple diagnostic indicator of eSOD activity levels in the epididymis.
Introduction
The role of free radicals in the pathology and physiology of human spermatozoa has been the subject of intensive investigation, particularly over the past two decades, following the pioneering work of MacLeod (1943) , Tosic and Walton (1950) and Mann (1964) . Spermatozoa are especially sensitive to reactive oxygen species (ROS) and lipid hydroperoxides (Jones and Mann, 1977; Mann and Lutwak-Mann, 1981) since their membranes are unusually rich in polyunsaturated phospholipids. Elevated ROS values can lead to increased membrane permeability, anatomical abnormalities and loss of fertility (Alvarez and Storey, 1989; Aitken and Clarkson, 1987; Iwasaki and Gagnon, 1992) . Spermatozoa are exposed to ROS at many stages during their transit through the male and female reproductive tracts. First, the epithelial cells of the epididymis generate ROS as a consequence of their high rate of energy metabolism (Brooks, 1981) . Within semen, there are two additional sources of ROS; leukocytes are potentially the greatest producers (Barrett et al., 1992; Wolff, 1995) , although spermatozoa themselves may produce ROS using a membrane bound NADPH oxidase (Aitken et al., 1989; 1992a,b) . Finally, capacitation within the female reproductive tract appears to be an oxidative event with both superoxide radicals and hydrogen peroxide implicated in the process (Bize et al., 1991; Gagnon, 1993, 1995; Griveau et al., 1995) .
Human spermatozoa, in common with those of most mammals, appear to possess a number of defensive mechanisms to prevent ROS damage. Their cytoplasm contains superoxide dismutase (Alvarez et al., 1987) , glutathione peroxidase/reductase (Alvarez and Storey, 1989) and catalase (Jeulin et al., 1989) to counteract internally-generated ROS. Within the epididymis itself, cytosolic Cu/Zn SOD has been localized to the basal cells of the epithelium (Nonogaki et al., 1992) , and in the rat, the epididymis is also the site of expression of an abundant extracellular SOD (eSOD) isoenzyme (Perry et al., 1993) and an abundant, extracellular glutathione peroxidase (Perry et al., 1992) , both of which are secreted into the epididymal fluid. In view of its high level of expression, we believe that this extracellular SOD may play an important role in neutralizing superoxide radicals present in epididymal fluid, whereupon the extracellular glutathione peroxidase could remove the resulting hydrogen peroxide.
Extracellular superoxide dismutase (eSOD) is not specific to the male reproductive tract, indeed it is the major SOD isoenzyme in the extracellular matrix of most tissues, as well as occurring in extracellular fluids such as plasma and lymph (Marklund 1984; Sandstrom et al., 1993; Oury et al., 1996) . Human eSOD is a tetrameric protein composed of four 35 kDa subunits (Oury et al., 1996) , present in three subtypes (A, B and C) classified according to affinity for heparin (Marklund et al., 1982; Karlsson and Marklund, 1987; 1988a,b) . The heparin binding site is located at the carboxyterminal end of the protein, in a tight cluster of arginine and lysine residues, forming a positively charged domain (Adachi and Marklund, 1989) . The heterogeneity of heparin binding within eSOD is a result of proteolysis of the carboxy-terminus of the protein, causing loss of the positively-charged domain responsible for heparin binding, without affecting the activity of the enzyme (Sandstrom et al., 1992) . However, proteolysis is not the only way in which the heparin binding properties of eSOD may be reduced. Adachi et al. (1991) reported that glycosylation of the C-terminus reduces heparin binding but enzymic activity is unaffected. These events indicate that whilst the majority of eSOD is bound to membranes via heparin sulphate, a number of processes exist that will liberate fully active enzyme into extracellular fluids.
Although expressed in a range of different tissues, the epididymis has been shown to be a major site of eSOD expression in the rat (Perry et al., 1993) , with the highest transcript levels in the cauda region, consistent with the high levels of SOD enzyme activity found in cauda epididymal plasma. As an essential prelude to investigating the role of this enzyme in sperm protection in the human, and its possible involvement in some forms of reduced male fertility, a source of antiserum was required which could distinguish between human eSOD and the other human SOD isoenzymes, in particular the Cu/Zn SOD associated with contaminating macrophages and leukocytes. This could conveniently be achieved by raising antisera against a recombinant protein obtained by expressing part of human eSOD cDNA (a part exhibiting maximum disparity to other SOD isoenzymes) in a bacterial expression system.
Materials and methods
Preparation and cloning of human eSOD synthetic oligonucleotides Single stranded oligonucleotides (each~65 bp in length; see Figure  1 for sequences) were synthesized on a PerSeptive Biosystems Expedite ® DNA synthesizer (Hertford, UK) using standard phosphoramidite chemistry and used without further purification. They were 5Ј-phosphorylated with T4 polynucleotide kinase. After incubating each oligonucleotide [1 mg/ml in 10 mM Tris-HCl, pH 7.6 containing 1 mM ethylenediaminetetraacetic acid (EDTA; Amersham Pharmacia Biotech, St Albans, UK); at 100°C for 5 min to break any secondary structure, two complementary oligonucleotides were mixed and allowed to cool to room temperature to anneal. They were then ligated into appropriately-cut pUC18 or Bluescript ® (Stratagene Ltd., Cambridge, UK) plasmid vector. Fragment I (see Figure 1 ) was not produced with cohesive, overhanging termini and as a result was blunt-end ligated into the unique SmaI site of pUC18 in order to utilize all of the possible restriction sites within the multicloning site of pUC18. This was necessary as fragment I contained a BamHI site and fragment II a KpnI site. Ligation of fragment I at the EcoRI/ BamHI site of pUC18 would have deleted the KpnI site and made insertion of the second fragment impossible (see Figure 2 ). All other fragments (II to V) were synthesized with cohesive, overhanging termini to facilitate ligation into the appropriately-cut vectors (Figure 2 ).
Assembly of synthetic human eSOD gene fragment
The overall assembly of the synthetic human eSOD gene fragment is depicted in Figure 2 .
Fragment I was excised from recombinant plasmid pSOD-I with BamHI (along with a few nucleotides of the vector's multicloning site at the 5Ј end) and religated into the BamHI site of recombinant 236 plasmid pSOD-II containing fragment II. One resulting recombinant plasmid (pSOD-I/II) with fragments I and II in the correct orientation relative to each other was selected for further assembly.
Fragment III was excised from recombinant plasmid pSOD-III with KpnI/XbaI and religated into recombinant plasmid pSOD-IV containing fragment IV, linearized with KpnI/XbaI, thereby producing pSOD-III/IV.
Combined fragments I and II were then excised from pSOD-I/II with EcoRI/KpnI and religated into pSOD-III/IV, linearized with EcoRI/KpnI, to produce plasmid pSOD-I/II/III/IV. The combined insert in pSOD-I/II/III/IV was excised with EcoRI/HindIII and religated into Bluescript ® plasmid vector [pSOD-(Bluescript ® )-I/II/III/IV] to facilitate subsequent insertion of fragment V. Crude bacterial cell lysates containing this fusion protein, obtained by sonication, were affinity-purified on an amylose-agarose resin column (New England Biolabs). Peak fractions containing the MBPeSOD fusion protein were identified on sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) gels stained with Coomassie Brilliant Blue R-250.
Production of polyclonal antisera to recombinant MBPeSOD fusion protein
Polyclonal antisera to the purified MBP-eSOD fusion protein were raised in rabbits by the Antibody Facility of the BBSRC Babraham Institute (Babraham, Cambridge, UK). Following collection of preimmune serum samples, two New Zealand White rabbits (K238 and K239) were immunized with 100-200 µg of purified fusion protein in complete Freund's adjuvant. Animals were then boosted with a further 100 µg of antigen (in incomplete Freund's adjuvant) after 4, 6 and 8 weeks, test bleeds being taken just before each booster. After 8 weeks the animals were killed, serum collected, and stored in aliquots at -80°C. Antiserum from rabbit K239 was found to give the strongest response on preliminary Western blots and was chosen for all subsequent work.
Preparation of human seminal plasma samples
Randomly-selected semen samples were obtained from men with normal semen characteristics attending a donor insemination clinic associated with the University of Bristol's Department of Obstetrics and Gynaecology. For comparison, a semen sample was also obtained from a man who had undergone a vasectomy 12 years previously.
Isotonic Percoll (100%; Sigma Chemical Co, Poole, Dorset) was prepared using 10ϫ modified Biggers-Whitten-Whittingham medium (BWW; Aitken, 1983) . A 40/80% discontinuous gradient was then prepared using appropriate dilutions of this 100% Percoll with BWW medium. 1 ml of fresh semen was then layered on top of the gradient and centrifuged at 350 g for 10 min to pellet cells. Sperm-free seminal Figure 1 . Sequence of a human artificial eSOD gene fragment. The synthetic human eSOD 'gene' fragment was designed to reduce the GC composition whilst maintaining the amino acid sequence of residues 1-93 of the authentic, mature protein. In addition, a number of unique restriction sites (shown boxed) were engineered into the designed gene to facilititate its construction from a series of synthetic oligonucleotides (Fragments I to V; see text for details). plasma was aspirated from the upper layer and stored at -20°C until required.
Preparation of human tissue extracts
Proteins were extracted from human tissues (post-mortem or removed during surgery) by homogenization in phosphate-buffered saline (PBS; 154 mM NaCl, 1.9 mM NaH 2 PO 4 , 8.1 mM Na 2 HPO 4 , pH 7.2) containing 1 mM 4-(2-aminoethyl) benzenesulphonyl fluoride (ICN Biomedicals Inc, Ohio, USA) followed by incubation on ice for 1 h, with occasional vortexing, in the same buffer containing 1% Triton-X100 (Sigma Chemical Co). Homogenates were then centrifuged at 10 000 g and supernatants stored at -20°C until required.
Western blot analysis human eSOD
Protein extracts and seminal plasma samples were separated by SDS-PAGE (Laemmli, 1970) on 12% polyacrylamide gels under reducing conditions and subsequently blotted onto polyvinylidene difluoride (PVDF) membranes (PolyScreen™; NEN Life Science Products, Brussels). Blots were probed with human eSOD-specific polyclonal antiserum (K238; 1:500 dilution in PBS) or pre-immune serum for 1 h. Membranes were then washed and incubated for 1 h with horseradish peroxidase (HRP)-conjugated swine anti-rabbit immunoglobulins (1:2000 dilution in PBS; Dako Ltd., High Wycombe, UK) as the secondary antibody. Subsequent detection of bound antibody was achieved using enhanced chemiluminescence (Amersham ECL ® ; Amersham International, Amersham, UK) and exposure of membranes to Hyperfilm ® (Amersham). Molecular masses were estimated from the relative mobilities of protein standards (Bio-Rad Labs. Ltd, Herts, UK) in adjacent lanes, stained with Coomassie Brilliant Blue R-250.
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Protein concentration of tissue homogenates was determined using the Bradford assay (Bradford, 1976) .
Results

Preparation of a synthetic human eSOD synthetic gene fragment
Unfortunately, human eSOD (Hjalmarsson et al., 1987) is extremely GC-rich (Ͼ70%) throughout its transcript; particularly noticeable within the coding region (Ͼ75% GC content). Not only does this make the cDNA cloning difficult (reverse transcriptase is particularly sensitive to GC-rich regions, causing frequent premature termination of cDNA synthesis), even once cloned in E.coli the subsequent expression is likely to be very inefficient. For example, E.coli has difficulty in transcribing GC-rich DNA, GC-rich regions may act as inappropriate Shine-Dalgarno sequences, resulting in incorrect translational initiation, and the atypical codon usage of GCrich DNA is likely to be detrimental to achieving efficient protein expression levels. With these problems in mind, it was decided to construct an artificial gene for part of human eSOD, based on a series of synthetic oligonucleotides, replacing the authentic GC-rich codons with the optimal E.coli synonyms.
Comparison of the amino acid sequence of human eSOD with those of the other human SOD isoenzymes revealed significant sequence similarity between eSOD and cytosolic Cu/Zn SOD over the C-terminal half of the protein molecules, but no similarity within the first 100 amino acid residues of the eSOD protein. Consequently, the region chosen for synthetic gene construction was based on the first 93 residues of mature human eSOD (i.e. without the signal peptide sequence).
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Synthetic oligonucleotides which are complementary over part of their length will anneal under appropriate conditions to generate double-stranded molecules. If such oligonucleotides are designed to include single-stranded overhanging termini, corresponding to restriction site cohesive ends, a series of these double-stranded oligonucleotides can be subsequently ligated together, via their mutually complementary termini, to generate a long segment of DNA. Thus it is feasible to synthesize reasonably large 'genes' with a codon usage most appropriate for the organism in which the protein is to be expressed. Since the degeneracy within the genetic code allows some flexibility in the choice of codon usage, unique restriction sites can usually be incorporated to facilitate cloning, without altering the amino acid sequence of the encoded polypeptide.
Unlike other SOD isoenzymes, human eSOD transcripts show a definite codon bias towards GC-rich codons, with most codons displaying a G or C in the third base position. In order to overcome this acute GC bias, the eSOD amino acid sequence was back-translated using optimal E.coli codons. To facilitate subsequent assembly and cloning of a large eSOD synthetic gene fragment (~300 bp), unique restriction sites were engineered into the proposed sequence (see Figure 1) to permit the sequential ligation of a series of shorter oligonucleotides (about 60-70 bp) into a suitable plasmid as described in the Materials and methods section and summarized in Figure 2 . These unique restriction sites were carefully chosen by scanning all possible codon usages at intervals of about 60 bp along the proposed synthetic gene sequence, whilst at the same time avoiding changing the sequence of the encoded polypeptide.
Localization of human eSOD by Western blotting
The human eSOD synthetic gene fragment encoded the first 93 amino acids of the mature, full-length human protein; the region exhibiting maximum sequence disparity between eSOD and cytosolic SOD isoforms. Polyclonal antisera raised against this eSOD protein fragment should therefore show a high level of specificity towards eSOD.
A polyclonal antiserum (K239) raised in rabbits against the recombinant human eSOD fusion protein was found to produce a strong reaction with the bacterially-expressed fusion protein on Western blots at dilutions of 1:250 and 1:500, indicating a good immunological response against the chosen antigen, with no reaction using the corresponding preimmune serum (data not shown).
Western blots of human tissue homogenates (testis, uterus, prostate, placenta, heart) and human seminal plasma, prepared from SDS-PAGE gels run under stringent reducing conditions (Oury et al., 1996) and probed with K239 antiserum, showed the widespread distribution of eSOD within the tissues of the reproductive tract (Figure 3) . In each case, human eSOD was predominantly identified as a dimeric 64 kDa band (Figure 3) . No reaction was observed with preimmune serum or with the secondary antibody alone (horseradish peroxidase-conjugated swine anti-rabbit immunoglobulins). As expected from the design of the synthetic gene fragment, no cross-reaction with cytosolic Cu/Zn SOD (16 kDa) was observed on Western blots (data not shown).
Homogenized human testis tissue preparations displayed a 64 kDa dimer band on Western blots, with no evidence of a monomeric band, even after boiling samples for 10 min under reducing conditions of 60 mM dithiothreitol (DTT) or 4% β-mercaptoethanol, or in the presence of 6 M urea (Figure 4 , panel A) prior to electrophoresis. In contrast, placental tissue homogenates displayed a series of eSOD monomer bands, in the range 30-34 kDa, in addition to a prominant dimer band (Figure 4 , panels A and B), even in the absence of β-mercaptoethanol (Figure 4, panel B) . The monomer bands were separate and distinct, probably reflecting the different eSOD subtypes (see Introduction). Whilst the general stability of eSOD dimers to reduction and denaturation has previously been observed by others (e.g. Oury et al., 1996) , the greater stability of testis-derived eSOD compared with placentalderived eSOD is an intriguing finding. Observed differences between testis and placenta may arise due to differing conditions within these tissues. For example, placenta is rich in proteases and is capable of reducing eSOD to its monomeric state. Indeed Sandstrom et al. (1993) found that placenta contains all three heparin binding subtypes, but only one form was present in testis.
Attempts to prevent dimerization of eSOD by alkylation with iodoacetamide failed to produce a detectable amount of monomer on Western blots (data not shown), suggesting that the intersubunit interaction is not simply due to disulphide bond formation.
Detection of eSOD in human seminal plasma by Western blotting
The presence of eSOD within human seminal plasma (see Figure 3) was investigated further by Western blot analysis of samples from five randomly-selected men with normal semen characteristics. Using K239 antiserum, eSOD was detected (as a dimer) in all five seminal plasma samples, in approximately equivalent amounts ( Figure 5 ). However, similar western blot analysis of a seminal plasma sample obtained from a vasectomized man also indicated the presence of a comparable amount of eSOD ( Figure 5 ), suggesting that the majority of eSOD present in seminal plasma is not derived from epididymal secretions, but rather from the prostate (see Figure 3) and perhaps other accessory organs. Consequently, analysis of eSOD levels in seminal plasma is not a good diagnostic indicator of enzyme levels in the epididymis. were electrophoresed on a 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel following exposure (100°C for 10 min) to reducing agents: 0, 1, 2 or 4% β-mercaptoethanol (BME) or 60 mM dithiothreitol (DTT) or 6 M urea. After blotting, the polyvinylidene difluoride (PVDF) membrane was probed with an anti-MBP-eSOD antiserum (K239; 1:500 dilution). (donors 310, 33, 331, 333, 335) and one vasectomized man. Protein (100 µg) was electrophoresed on a 15% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel, blotted onto a polyvinylidene difluoride (PVDF) membrane and probed with an anti-MBP-eSOD antiserum (K239; 1:500 dilution).
Discussion
Paradoxically, human spermatozoa rely on redox-regulated processes for some aspects of their function (e.g. capacitation is an oxidative process), yet their membranes, which are rich in unsaturated fatty acids (thereby providing the fluidity for membrane fusion during fertilization), are particularly vulnerable to oxygen free radical-induced peroxidative damage (reviewed by Aitken, 1997 and Storey, 1997) . Whilst spermatozoa do possess protective enzymes (superoxide dismutase and glutathione peroxidase) within their cytoplasm, the limited cytoplasmic volume and localization limits the effectiveness of these intracellular antioxidant enzymes. Consequently, the fluids surrounding maturing spermatozoa in the epididymis and following ejaculation are additional rich sources of antioxidant enzymes. For example, in the rat, secreted isoforms of glutathione peroxidase (Perry et al., 1992) and superoxidase dismutase (Perry et al., 1993) are abundantly expressed by the epididymis and have been proposed to play important roles in protecting spermatozoa from oxidative damage. In the human, many independent studies have suggested a role for elevated levels of ROS as a contributory factor in some cases of reduced male fertility (see Aitken, 1997 and Storey, 1997) .
Within the male reproductive tract, ROS are generated by contaminating leukocytes (particularly neutrophils), as well as by spermatozoa themselves. In the latter case, increased levels of ROS have recently been associated with increased retention of residual cytoplasm following spermiation (Gomez et al., 1996) . It has been proposed (see Aitken, 1997 ) that spermatozoa with an excess of residual cytoplasm will therefore possess an increased amount of the cytosolic enzyme, glucose-6-phosphate dehydrogenase. This enzyme is involved in generating NADPH, an increase in which will lead to elevated production of ROS and hence the potential for increased lipid peroxidative damage.
Many studies have suggested that SOD plays an important role in protecting human spermatozoa from peroxidative damage; indeed in some cases a correlation has been suggested between SOD enzyme concentration (which may vary widely between individuals) and sperm quality, assessed by measuring, for example, the time to complete loss of motility (TLM) (for review see Alvarez et al., 1987; Storey, 1997) . However, such studies are complicated by the presence of various contaminating SOD isoenzymes, derived from contaminating leukocytes and macrophages, which may contribute to SOD activity assayed in vitro but may not be active in protecting spermatozoa in vivo. In an attempt to overcome these difficulties we have taken an immunological approach to demonstrate the presence of eSOD in the human male reproductive tract using an eSOD isoenzyme-specific polyclonal antiserum. This eSOD antiserum was raised against a recombinant protein containing the first 93 amino acid residues of mature human eSOD, expressed from a synthetic gene fragment. Using this antiserum (K239), which is specific for the eSOD isoenzyme, it has been demonstrated that high levels of eSOD protein are expressed in a range of reproductive tissues. Taken together with the finding of high levels of eSOD transcripts within the epididymis (Perry et al., 1993) , this would strongly suggest an important role for this enzyme in the defence of spermatozoa against superoxide radicals during epididymal transit and storage. However, whilst eSOD's role within the male reproductive tract is arguably important, it should be borne in mind that initial studies with eSOD knockout mice (Carlsson et al., 1995) have indicated that they are fertile. Nevertheless, proper fertility studies have yet to be undertaken to evaluate the true fertilizing ability of these mice or the damage sustained to their sperm membranes. Although still fertile, these mice may have a significantly reduced sperm count due to free radical damage.
A major aim of the work described in this paper was to produce a specific antiserum for the detection of human eSOD (as opposed to other SOD isoenzymes), to determine whether men with elevated free radical levels in their seminal plasma (and by inference, epididymis) have reduced levels of eSOD in their seminal plasma, thereby providing a simple diagnostic indicator. Unfortunately from a diagnostic point of view, high levels of eSOD were also found to be present in the seminal plasma following vasectomy, indicating that much of the eSOD found in ejaculates is probably derived from accessory organs including the prostate. Whilst such findings do not preclude an important role for eSOD in the epididymis, attempts to correlate elevated free radical levels and sperm lipid peroxidative damage with reduced eSOD activity in the epididymis, would clearly require direct assays on epididymal fluid; a diagnostic approach which is not practical in the human.
